Close

The North Carolina Seqirus Factory Gets A $156mn Upgrade

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

The Ultimate Pain Relief Guide: Proven Tips to Manage Discomfort Naturally

Pain is something that we all go through somehow...

Seqirus recently completed a $156 million expansion plan at its Holly Springs, North Carolina, fill-finish production plant, which began in 2018. The expanded facility, along with the recent FDA approval of its new prefilled syringe line, puts Seqirus in a position to help influenza vaccine manufacturing for the forthcoming seasonal flu period and even beyond, the company said. The project was originally estimated to cost $140 million and be completed by 2020, just in time for the COVID-19 pandemic.

The facility, which will produce Flucelvax Quadrivalent, the first and only cell-based influenza vaccine for people between the ages of 6 months and older, will add more than 80 new skilled positions. Fluad Quadrivalent influenza jabs for adults aged 64 and older will also be produced in the facility.

This new line allows them to more efficiently simplify their production, allowing the organisation to meet the needs of the clients and, as a result, better fulfil the needs of public health, said Dave Ross, vice president, Dave Ross of Seqirus’ North American operations. The Holly Springs factory was producing only 3 million doses of cell-based vaccines per year when CSL purchased Novartis’ vaccine group and established Seqirus in 2015. The factory was built as part of a 2006 public-private partnership with the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA).

BARDA hired Seqirus in 2021 to research two influenza A vaccine candidates for a phase I clinical trial as part of its pandemic preparedness efforts. The company claims it can now deliver up to 150 million influenza vaccine doses to assist in an influenza pandemic emergency as well as cover seasonal influenza vaccine production thanks to the increase.

Latest stories